Previous 10 | Next 10 |
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine PR Newswire – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T...
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine PR Newswire – Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – C...
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment a...
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference PR Newswire Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial SAN JOSE, Calif. , Oct. 31, 2023 /PRNewswire/ -- Anixa Biosci...
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board PR Newswire SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA...
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial PR Newswire - With no dose-limiting toxicities observed, treatment of second dose cohort to begin SAN JOSE, Calif. , Oct. 13, 2023 /PRNewswire/ -- Anixa...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused...
Anixa Biosciences to Participate in September Investor Conferences PR Newswire SAN JOSE, Calif. , Aug. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention ...
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif. , Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused o...
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit PR Newswire SAN JOSE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c...
News, Short Squeeze, Breakout and More Instantly...
Anixa Biosciences Inc. Company Name:
ANIX Stock Symbol:
NASDAQ Market:
Anixa Biosciences Inc. Website:
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment an...
Anixa Biosciences Announces $5 Million Share Repurchase Program PR Newswire SAN JOSE, Calif. , July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of ...
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial PR Newswire This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif. , June 24, 2024 /PRNewswire/ -- Anixa Biosciences, I...